Emerging drugs for the treatment of acne

@article{Aslam2015EmergingDF,
  title={Emerging drugs for the treatment of acne},
  author={Imran Aslam and Alan B. Fleischer and Steven R. Feldman},
  journal={Expert Opinion on Emerging Drugs},
  year={2015},
  volume={20},
  pages={101 - 91}
}
Introduction: Acne is the most common skin condition in the US. The mainstay of acne therapy includes: topical retinoids, topical antibiotics, benzoyl peroxide (BP), and oral isotretinoin for severe cases. Although these treatment options are highly effective they do have certain drawbacks. Current acne treatment regimens often require patients to use multiple medications, some of which may have irritating side effects. Furthermore, Propionibacterium acnes resistance to antibiotics has become… Expand
Evaluating FMX-101 as a promising therapeutic for the treatment of acne
TLDR
The proven efficacy and safety profile of FMX-101, together with the low systemic absorption, high skin tolerability and cosmetically acceptable foam formulations render this novel therapy an important addition to the acne treatment armamentarium. Expand
Emerging Therapies for Acne Vulgaris
TLDR
Therapies for acne are constantly evolving and current gold-standard acne therapy may be supplemented with novel treatment modalities in the near future. Expand
Minocycline Topical Foam: A New Drug for the Treatment of Acne
TLDR
The foam has a good safety profile, with headache, mild erythema, hyperpigmentation, and mild dryness among the most common adverse effects and may help restore this important therapeutic approach for treating acne vulgaris. Expand
What's new in acne and rosacea?
  • J. Keri
  • Medicine
  • Seminars in cutaneous medicine and surgery
  • 2016
TLDR
This review will discuss the most recent therapeutic options for patients with acne and rosacea, and the new topical agents - brimonidine gel and ivermectin cream - will be reviewed, with a discussion on possible rebound phenomenon from Brimonidine. Expand
A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne.
TLDR
In silico screening showed that one of the molecules, VCD-004, exhibits improved mode of binding to bacterial DNA gyrase, suggesting that it impedes the development of resistance better than clindamycin. Expand
Antibiotic resistance to Propionobacterium acnes: worldwide scenario, diagnosis and management
TLDR
Genomic evaluation using 16S ribosomal RNA gene sequencing can be useful in diagnosing mutations and mapping phylotypes of Propionobacterium acnes, and the use of oral retinoids and non-antibiotics like zinc can prevent resistance and help reduce the dependence on antibiotics. Expand
Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects
TLDR
VB-1953 topical gel appears to be safe for use in adults with facial acne vulgaris and may offer new advances as a topical antibiotic agent for the disease. Expand
Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes
TLDR
Results indicate that VB-1953 topical gel can be a safe and effective therapy for moderate to severe acne with underlying resistant C. acnes in subjects who had not responded to previous antibiotic treatments. Expand
Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris
TLDR
Findings support sarecycline as a narrow-spectrum tetracycline-class antibiotic that is effective for the treatment of acne, and further investigation into the potential reduced effects on the gut microbiome compared with those of other agents is warranted. Expand
Acne vulgaris
TLDR
New treatment options with a shift towards targeting the early processes involved in acne development instead of suppressing the effects of end products will enhance the ability to improve the outcomes for patients with acne. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 72 REFERENCES
Novel pharmacological approaches for the treatment of acne vulgaris
TLDR
The authors believe that there will likely be a decline in the use of antibiotics for controlling P. acnes colonization and targeting the inflammation cascade, and Retinoic acid metabolism-blocking agents and IL-1α inhibitors have the potential to become legitimate alternative options to retinoid therapy in the management of infundibular dyskeratosis. Expand
Novel pharmacological approaches for the treatment of acne vulgaris.
TLDR
The authors discuss and evaluate the pathogenic pathways related to the mechanisms of action of novel molecules, which are currently under investigation for the treatment of acne vulgaris. Expand
Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris.
TLDR
The once daily use of CTG, its rapid and dual effect and good tolerability have a positive impact on the duration of disease, patients' compliance and overall costs of therapy. Expand
Subantimicrobial dose doxycycline for acne and rosacea.
TLDR
Subantimicrobial dose doxycycline (Periostat 20 mg) has clinical utility in periodontitis and has been investigated in a double-blind, placebo-controlled, and open label study in the treatment of rosacea. Expand
Safety and side effects of the acne drug, oral isotretinoin.
TLDR
The most common adverse events, observed during treatment, are mucocutaneous and ophthalmological and laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary and other systems have been described. Expand
Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.
TLDR
Subantimicrobial-dose doxycycline administered twice daily for 3 months in patients with moderate inflammatory acne results in significant reduction in the number of total inflammatory lesions. Expand
Tolerability of topical antimicrobials in treatment of acne vulgaris.
TLDR
Tolerability of topical antimicrobial therapy for acne may not have great clinical significance, and patients may be more adherent in clinical trials than in clinical practice. Expand
A Novel Gel Formulation of 0.25% Tretinoin and 1.2% Clindamycin Phosphate: Efficacy in Acne Vulgaris Patients Aged 12 to 18 Years
TLDR
This novel CLIN/RA gel for treating acne is tolerable and safe and offers clinicians and teen aged patients a new and efficacious intervention for acne vulgaris. Expand
Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
TLDR
Results show that dapsone gel 5% is safe and effective for long-term treatment of acne vulgaris and has a rapid onset of action. Expand
Topical ALA-photodynamic therapy for the treatment of acne vulgaris.
TLDR
There was clinical and statistically significant clearance of inflammatory acne by aminolevulinic acid plus red light, for at least 20 wk after multiple treatments and 10 wK after a single treatment, in an open-label prospective human study of acne vulgaris. Expand
...
1
2
3
4
5
...